Asian Pacific Journal of Cancer Prevention

Asian Pacific Journal of Cancer Prevention (아시아태평양암예방학회)
권호 표지
DOI QR코드

DOI QR Code

Association of DR4 (TRAIL-R1) Polymorphisms with Cancer Risk in Caucasians: an Updated Meta-analysis

  • Chen, Wei (Faculty of Medicine, Kunming University of Science and Technology) ;
  • Tang, Wen-Ru (Faculty of Medicine, Kunming University of Science and Technology) ;
  • Zhang, Ming (Faculty of Life Science and Technology, Kunming University of Science and Technology) ;
  • Chang, Kwenjen (Faculty of Life Science and Technology, Kunming University of Science and Technology) ;
  • Wei, Yun-Lin (Faculty of Life Science and Technology, Kunming University of Science and Technology)
  • Published : 2014.03.30
Download PDF
⟨ Previous Next ⟩

Abstract

Death receptor 4 (TRAIL-R1 or DR4) polymorphisms have been associated with cancer risk, but findings have been inconsistent. To estimate the relationship in detail, a meta-analysis was here performed. A search of PubMed was conducted to investigate the association between DR4 C626G, A683C and A1322G polymorphisms and cancer risk, using odds ratios (ORs) with 95% confidence intervals. The results suggested that DR4 C626G and A683C polymorphisms were indeed associated with cancer risk (for C626G, dominant model, OR 0.991, 95%CI 0.866-1.133, p=0.015; for A683C, additive model, OR=1.140, 95%CI: 0.948-1.370, p=0.028; dominant model, OR=1.156, 95%CI: 0.950-1.406, p=0.080) in the Caucasian subgroup. However, the association was not significant between DR4 polymorphism A1322G with cancer risk in Caucasians (For A1322G, additive model: OR 1.085, 95%CI 0.931-1.289, p=0.217; dominant model: OR 1.379, 95%CI 0.934-2.035, p=0.311; recessive model: OR 1.026, 95%CI 0.831-1.268 p=0.429.). In summary, our finding suggests that DR4 polymorphism C626G and A683 rather than A1322G are associated with cancer risk in Caucasians.

Keywords

References

  1. Bouralexis S, Findlay DM, Evdokiou A (2005). Death to the bad guys: targeting cancer via Apo2L/TRAIL. Apoptosis, 10, 35-51. https://doi.org/10.1007/s10495-005-6060-0
  2. Chen B, Liu S, Wang XL, et al (2009). TRAIL-R1 polymorphisms and cancer susceptibility: an evidence-based meta-analysis. Eur J Cancer, 45, 2598-605. https://doi.org/10.1016/j.ejca.2009.06.023
  3. DerSimonian R, Laird N (1986). Meta-analysis in clinical trials. Control Clin Trials, 7, 177-88. https://doi.org/10.1016/0197-2456(86)90046-2
  4. Egger M, Davey Smith G, Schneider M, et al (1997). Bias in meta-anaysis detected by a simple, graphical test. BMJ, 315, 629-34. https://doi.org/10.1136/bmj.315.7109.629
  5. Evan GI, Vousden KH (2001). Proliferation, cell cycle, and apoptosis in cancer. Nature, 411, 342-8. https://doi.org/10.1038/35077213
  6. Fernandez V, Jares P, Bea S, et al (2004). Frequent polymorphic changes but not mutations of TRAIL receptors DR4 and DR5 in mantle cell lymphoma and other B-cell lymphoid neoplasms. Haematologica, 89, 1322-31.
  7. Fisher MJ, Virmani AK, Wu L, et al (2001). Nucleotide substitution in the ectodomain of TRAIL receptor DR4 is associated with lung cancer and head and neck cancer. Clin Cancer Res, 7, 1688-97.
  8. Frank B, Hemminki K, Shanmugam KS, et al (2005). Association of death receptor 4 haplotype 626C-683C with an increased breast cancer risk. Carcinogenesis, 26, 1975-7. https://doi.org/10.1093/carcin/bgi164
  9. Frank B, Shanmugam KS, Beckmann L, et al (2006). Death receptor 4 variants and colorectal cancer risk. Cancer Epidemiol Biomarkers Prevent, 15, 2002-5. https://doi.org/10.1158/1055-9965.EPI-06-0053
  10. Hazra A, Chamberlain RM, Grossman HB, et al (2003). Death receptor 4 and bladder cancer risk. Cancer Res, 63, 1157-9.
  11. Hengartner MO (2000). The biochemistry of apoptosis. Nature, 407, 770-6. https://doi.org/10.1038/35037710
  12. Horaka P, Pilsa D, Roesslera M, et al (2005). Common death receptor 4 (DR4) polymorphisms do not predispose to ovarian cancer. Gynecol Oncol, 97, 514-8. https://doi.org/10.1016/j.ygyno.2005.01.021
  13. Kim H, Ku SY, Suh CS, et al (2012). Association between endometriosis and polymorphisms in tumor necrosis factorrelated apoptosis-inducing ligand (TRAIL), TRAIL receptor and osteoprotegerin genes and their serum levels. Arch Gynecol Obstet, 286, 147-53. https://doi.org/10.1007/s00404-012-2263-0
  14. Koornstra JJ, Kleibeuker JH, Van Geelen CM, et al (2003). Expression of TRAIL (TNF-related apoptosis-inducing ligand) and its receptors in normal colonicmucosa, adenomas, and carcinomas. J Pathol, 200, 327-35. https://doi.org/10.1002/path.1364
  15. Korner C, Riesner K, Kramer B, et al (2012). TRAIL receptor I (DR4) polymorphisms C626G and A683C are associated with an increased risk for hepatocellular carcinoma (HCC) in HCV-infected patients. BMC Cancer, 12, 85. https://doi.org/10.1186/1471-2407-12-85
  16. Kuraoka K, Matsumura S, Sanada Y, et al (2005). A single nucleotide polymorphism in the extracellular domain of TRAIL receptor DR4 at nucleotide 626 in gastric cancer patients in Japan. Oncol Rep, 14, 465-70.
  17. MacFarlane M, Ahmad M, Srinivasula SM, et al (1997). Identification and molecular cloning of two novel receptors for the cytotoxic ligand TRAIL. J Biol Chem, 272, 25417-20. https://doi.org/10.1074/jbc.272.41.25417
  18. Mantel N, Haenszel W (1959). Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst, 22, 719-48.
  19. Martinez-Ferrandisa JI, Rodriguez-Lovcvpez R, Milnec RL, et al (2007). Polymorphisms in TRAIL receptor genes and risk of breast cancer in Spanish women. Cancer Biomark, 3, 89-93.
  20. Mittal RD, Srivastava P, Mittal T, et al (2011). Association of death receptor 4, Caspase 3 and 5 gene polymorphism with increased risk to bladder cancer in North Indians. EuR J Surg Oncol, 37, 727-33. https://doi.org/10.1016/j.ejso.2011.05.013
  21. Pan GH, Ni J, Wei YF, et al (1997). An antagonist decoy receptor and a death domain-containing receptor for TRAIL. Science, 277, 815-8. https://doi.org/10.1126/science.277.5327.815
  22. Pan GH, ORourke K, Chinnaiyan AM, et al (1997). The receptor for the cytotoxic ligand TRAIL. Science, 276, 111-3. https://doi.org/10.1126/science.276.5309.111
  23. Sprick MR, Weigand MA, Rieser E, et al (2000). FADD/MORT1 and caspase-8 are recruited to TRAIL receptors 1 and 2 and are essential for apoptosis mediated by TRAIL receptor 2. Immunity, 12, 599-609. https://doi.org/10.1016/S1074-7613(00)80211-3
  24. Tastemir-Korkmaz D, Demirhan O, Kuleci S, et al (2013). There is no significant association between death receptor 4 (DR4) gene polymorphisms and lung cancer in Turkish population. Pathol Oncol Res, 19, 779-84. https://doi.org/10.1007/s12253-013-9643-z
  25. Ulybina YM, Kuligina ES, Mitiushkina NV, et al (2009). Coding polymorphisms in Casp5, Casp8 and DR4 genes may play a role in predisposition to lung cancer. Cancer Lett, 278, 183-91. https://doi.org/10.1016/j.canlet.2009.01.012
  26. Wajant H, Pfizenmaier K, Scheurich P (2002). TNF-related apoptosis inducing ligand (TRAIL) and its receptors in tumor surveillance and cancer therapy. Apoptosis, 7, 449-59. https://doi.org/10.1023/A:1020039225764
  27. Wolf S, Mertens D, Pscherer A, et al (2006). Ala228 variant of trail receptor 1 affecting the ligand binding site is associated with chronic lymphocytic leukemia, mantle cell lymphoma, prostate cancer, head and neck squamous cell carcinoma and bladder cancer. Int J Cancer, 118, 1831-5. https://doi.org/10.1002/ijc.21502
  28. Yagita H, Takeda K, Hayakawa Y, et al (2004). TRAIL and its receptors as targets for cancer therapy. Cancer Sci, 95, 777-83. https://doi.org/10.1111/j.1349-7006.2004.tb02181.x

Cited by

  1. Association between Laryngeal Squamous Cell Carcinoma and Polymorphisms in Tumor Necrosis Factor Related Apoptosis Induce Ligand (TRAIL), TRAIL Receptor and sTRAIL Levels vol.15, pp.24, 2015, https://doi.org/10.7314/APJCP.2014.15.24.10697
  2. Evaluation of trail receptor 1 (DR4) polymorphisms C626G and A683C as risk factors of hepatocellular carcinoma pp.01466615, 2017, https://doi.org/10.1002/jmv.24964